Avenzo Therapeutics Initiates Phase I/II Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics, Inc.announced initiation of a Phase I/II clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, in patients with advanced solid tumors.